Extracted from this filing and checked against the source text.
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
Unity Biotechnology, Inc. received a nasdaq delisting notice notice regarding other (rules 5101, IM-5101-1, 5450(b)(1)(A), 5450(a)(1)).
- Exchange
- nasdaq
- Notice
- delisting notice
- Rules
- 5101, IM-5101-1, 5450(b)(1)(A), 5450(a)(1)
Exact text from the filing
urities on Nasdaq is no longer warranted. The Staff also cited its prior notification to the Company on March 14, 2025, as previously reported, that the Company was out of compliance with the minimum $10,000,000 stockholders’ equity requirement for continued listing set forth in Nasdaq Listing Rule 5450(b)(1)(A), as previously disclosed by the Company. In addition, as previously reported, on June 18, 2025, the Company received a separate letter from Nasdaq stating that for the last 30 consecutive business days, the closing bid price of the Company’s common stock was below $1.00 per share, whic
View on SEC.gov
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
Unity Biotechnology, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1)).
- Exchange
- nasdaq
- Notice
- noncompliance notice
- Deficiency
- minimum bid price
- Rules
- 5450(a)(1)
Exact text from the filing
June 18, 2025, the Company received a separate letter from Nasdaq stating that for the last 30 consecutive business days, the closing bid price of the Company’s common stock was below $1.00 per share, which is the minimum required closing bid price for continued listing on the Nasdaq Global Select Market pursuant to Listing Rule 5450(a)(1). Accordingly, Nasdaq, pursuant to its discretionary authority under Listing Rules 5101 and IM-5101-1, notified the Company that, unless the Company requests an appeal of these matters, trading of the Company’s common stock will be suspended at the opening of
View on SEC.gov